Below is an educational, technical answer to a question many patients and clinicians ask. Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery. Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture.
What is a drug-eluting stent and how does it work?
A drug-eluting stent is a small metallic scaffold coated with a polymer that gradually releases an antiproliferative drug into the artery wall. The scaffold props the vessel open while the drug is designed to suppress the tissue overgrowth that would otherwise cause restenosis. INVAMED's ATLAS DES pairs a cobalt-chromium platform with a sirolimus coating dosed at 1 microgram per square millimeter with sustained release. Whether a drug-eluting stent is appropriate for a given lesion is a decision made by the interventional cardiologist.
What This Means in Practice
Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes. Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting.
Key Considerations
- Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes.
- Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
- All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU.
Frequently Asked Questions
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
What is the reported restenosis performance of the ATLAS DES?
INVAMED reports clinical data showing target lesion revascularization rates below 5% at 12 months; this reflects studied performance and is not an individual guarantee.
Are these coronary devices CE marked?
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes. Because a drug-coated balloon leaves nothing behind, it is one option a clinician may weigh when a metallic implant is less desirable. INVAMED's Inwire PTCA Guidewire is offered for coronary wiring within the interventional line, alongside CTO and workhorse options. INVAMED's Atlas line spans a cobalt-chromium drug-eluting version, a bare cobalt-chromium version described as offering high radial strength with minimal recoil, and a stainless-steel version. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery. The need for extension support is judged case by case, since it depends on vessel geometry and the devices being delivered. Whether a closure device is used, and which type, is determined by access site, sheath size, and clinician preference.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- What should be avoided after stent placement?
- Sourcing Coronary Artery Disease & Cardiac Interventions Devices: A Manufacturer and Procurement Guide
- Drug-Eluting Stent (DES) Technology: Technology, Uses and Considerations
Important Disclaimer
The information here is provided for educational purposes and to describe device technology; it is not a substitute for professional medical advice, diagnosis, or treatment. Only a licensed healthcare provider can determine whether a given procedure or device is appropriate for a specific patient. INVAMED products are restricted to use by qualified professionals following the official IFU. Regulatory clearance and labeling differ between regions, and not all products or indications are available in every market.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.